Document is current
Any future updates will be listed below
-
Authors
Suleiman, Ahmed A.
Khatri, Amit
Oberoi, Rajneet K.
Othman, Ahmed A. https://orcid.org/0000-0002-4937-2775
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03000075 at ClinicalTrials.govnct03022045 at ClinicalTrials.govDocuments that mention this clinical trial
Exposure–Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis
https://doi.org/10.1007/s40262-019-00829-2
nct02672852 at ClinicalTrials.govDocuments that mention this clinical trial
Exposure–Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis
https://doi.org/10.1007/s40262-019-00829-2
nct02684357 at ClinicalTrials.govDocuments that mention this clinical trial
Exposure–Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis
https://doi.org/10.1007/s40262-019-00829-2
nct02684370 at ClinicalTrials.govDocuments that mention this clinical trial
Exposure–Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis
https://doi.org/10.1007/s40262-019-00829-2
nct02694523 at ClinicalTrials.govDocuments that mention this clinical trial
Exposure–Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis
https://doi.org/10.1007/s40262-019-00829-2
nct02054481 at ClinicalTrials.govDocuments that mention this clinical trial
Comparison of Drug-Free Remission after the End of Phase III Trials of Three Different Anti-IL-23 Inhibitors in Psoriasis
https://doi.org/10.1007/s13555-024-01229-6
Exposure–Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis
https://doi.org/10.1007/s40262-019-00829-2
Documents that mention this clinical trial
Exposure–Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis
https://doi.org/10.1007/s40262-019-00829-2
-
Funding
Funding for this research was provided by:
AbbVie
- License Information
-
More Information
Article History
First Online: 31 October 2019
Compliance with Ethical Standards
:
: This work was sponsored by Boehringer Ingelheim and AbbVie. Boehringer Ingelheim contributed to the study designs and data collection and AbbVie contributed to the analysis and interpretation of data, and the writing, review, and approval of the publication.
: Ahmed Suleiman is an AbbVie employee. Ahmed A. Othman, Amit Khatri, and Rajneet K. Oberoi are former employees of AbbVie. All authors may hold AbbVie stock or stock options.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual, and trial-level data (analysis data sets), as well as other information (e.g., protocols and Clinical Study Reports), provided the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications. These clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan and execution of a Data Sharing Agreement. Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered. For more information on the process, or to submit a request, visit the following link: .
